Seeking Alpha
16 Aug 2026, 13:32 UTC · 2h ago
HeartFlow: An Impressive MedTech Growth Play
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
16 Aug 2026, 13:32 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
HeartFlow achieved 48% sales growth in Q2 with gross margins increasing to 83%. — Strong top-line growth paired with high margins indicates significant scalability and operational efficiency.
+0.80The company raised its full-year revenue guidance to a range of $246–$250 million. — Upwardly revised guidance typically triggers positive price action as it signals confidence in future earnings.
+0.60The company is seeing expanding revenue from plaque-related services and commercial adoption of its non-invasive cardiac solution. — Product adoption and diversification of revenue streams support long-term growth sustainability.
+0.50Continue reading
6 related stories
Search tags
HeartFlow shares are currently trading at 13x sales. — This is a valuation metric that provides context but does not inherently drive price movement without a comparison to peers.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1h ago
